OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock. Separately, Needham & Company LLC reiterated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in […]

Leave a Reply

Your email address will not be published.

Previous post Pentair’s (PNR) Sector Weight Rating Reiterated at KeyCorp
Next post Jimmy Carter will be honored at Washington funeral before burial in Georgia hometown